Company news

Prescient Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

US FDA allows PTX-100 Ph2 trial

December 22, 2024

Appointment of Chief Executive Officer

December 17, 2024

September 2024 Quarterly Update and Appendix 4C

October 30, 2024

Prescient CEO to step down in early 2025

September 11, 2024

Appendix 4E and 2024 Annual Report

August 26, 2024

June 2024 Quarterly Update and Appendix 4C

July 31, 2024

March 2024 Quarterly Update and Appendix 4C

April 30, 2024

December 2023 Quarterly Update and Appendix 4C

January 31, 2024

PTX-100 Ph1b results show excellent safety & efficacy in TCL

December 10, 2023

September 2023 Quarterly Update and Appendix 4C

October 30, 2023

Appendix 4E and 2023 Annual Report

August 24, 2023

June 2023 Quarterly Update and Appendix 4C

July 26, 2023

March 2023 Quarterly Update and Appendix 4C

April 27, 2023

Continued promising results in PTX-100 TCL trial

March 15, 2023

FDA grants broader orphan drug status to PTX100 for TCLs

March 8, 2023

December 2022 Quarterly Update and Appendix 4C

January 25, 2023

AGM Presentation

November 29, 2022

September 2022 Quarterly Update and Appendix 4C

October 30, 2022

PTX-100 Trial Update

October 24, 2022

Placement Results

October 10, 2022

SPP Results and Placement

October 6, 2022

PTX unveils CellPryme-A to boost CAR-T performance

September 22, 2022

PTX strategic collaboration with MD Anderson Cancer Center

September 6, 2022

Prescient Therapeutics Launches Share Purchase Plan

August 24, 2022

Appendix 4E and 2022 Annual Report

August 23, 2022

PTX agreement with Thermo Fisher for scalable OmniCAR

August 17, 2022

PTX OmniCAR cell manufacturing contract for clinical trials

August 15, 2022

June 2022 Quarterly Update and Appendix 4C

July 24, 2022

US FDA Grants Orphan Drug Designation to PTX-100 for PTCL

July 14, 2022

Key OmniCAR Patent Granted in US

July 4, 2022

PTX CellPryme-M presentation

June 7, 2022

PTX unveils new clinic-ready CAR-T enhancement platform

June 7, 2022

PTX-200 AML expansion after another complete response

May 9, 2022

March 2022 Quarterly Update and Appendix 4C

April 28, 2022

Recruitment Open for Expansion Cohort of Phase 1B Study

April 5, 2022

December 2021 Quarterly Update and Appendix 4C

January 30, 2022

September 2021 Quarterly Activities and Appendix 4C

October 27, 2021

Investor Presentation - October 2021

October 12, 2021

PTX data demonstrates key OmniCAR features in next gen CAR-T

October 12, 2021

Appendix 4E and 2021 Annual Report

August 30, 2021

June 2021 Quarterly Activities and Appendix 4C

July 29, 2021

PTX-100 trial advances following successful Phase 1b

July 26, 2021

PTX successful immunogenicity testing of OmniCAR

July 4, 2021

PTX Completes CAR-T Manufacturing Milestone for OmniCAR

June 23, 2021

Response to ASX Price Query

June 3, 2021

PTX signs CAR-T agreement with Peter MacCallum

May 10, 2021

March 2021 Quarterly Update and Appendix 4C

April 29, 2021

PTX-200 AML Trial Progresses to Higher Dose

April 22, 2021

December 2020 Quarterly Update and Appendix 4C

January 27, 2021

PTX announces 3 next-gen CAR-T programs with OmniCAR

January 17, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 44 decks. Every deck is listed under its year.